Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof

Abstract

The present invention is directed to cell surface antigenes found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.

1. A method for detecting ovarian cancer in a patient comprising:
 a) obtaining a biological sample from the patient; 
 b) contacting the biological sample with a monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC®) as ATCC Accession Number PTA-450 or an antigen binding fragment thereof; and 
 c) detecting the complex formed by the monoclonal antibody and the antigen to which the antibody binds, 
 wherein the detection of the complex in the biological sample in an amount greater than an amount of the complex in a normal biological sample indicates the presence of ovarian cancer. 
 
     
     
       2. The methods of  claim 1  wherein the sample is contacted with the antigen binding fragment of the monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC®) as ATCC Accession Number PTA-450. 
     
     
       3. The method of  claim 2  wherein the antigen binding fragment is an F(ab′) 2 , Fab′, Fv, Fd′, or Fd. 
     
     
       4. The method of  claim 1  further comprising labeling the monoclonal antibody or antigen binding fragment thereof with a detectable moiety. 
     
     
       5. The method of  claim 4  wherein the detectable moiety is a fluorophore, a chromophore, a radionuclide, or an enzyme. 
     
     
       6. The method of  claim 1  wherein the biological sample is body fluid or tissue. 
     
     
       7. A method for detecting ovarian cancer in a patient comprising:
 a) obtaining a biological sample from the patient; 
 b) measuring in the biological sample a level of an antigen that binds to a monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC®) as ATCC Accession Number PTA450 or an antigen binding fragment thereof, wherein the antigen 
 (i) is a single polypeptide with a molecular weight of about 76 kDa to about 213 kDa as determined by SDS PAGE under reducing conditions; 
 (ii) is absent from human peripheral blood mononuclear cells, human B cells, and human B cell myelogenic leukemia cells; and 
 (iii) is glycosylated, 
 wherein the detection of the antigen in the biological sample in an amount greater than an amount of the antigen in a normal biological sample indicates the presence of ovarian cancer. 
 
     
     
       8. The method of  claim 7  wherein the antigen is detected by contacting the antigen with a monoclonal antibody which is produced by a hybridoma cell line deposited at the American Type Culture Collection (ATCC®) as ATCC Accession Number PTA-450 or an antigen binding fragment thereof. 
     
     
       9. The method of  claim 8  wherein the antigen binding fragment is an F(ab′) 2 , Fab′, Fv, Fd′, or Fd. 
     
     
       10. The method of  claim 8  further comprising labeling the monoclonal antibody or antigen binding fragment thereof with a detectable moiety. 
     
     
       11. The method of  claim 10  wherein the detectable moiety is a fluorophore, a chromophore, a radionuclide, or an enzyme. 
     
     
       12. The method of  claim 7  wherein the biological sample is body fluid or tissue. 
     
     
       13. The method of  claim 6  wherein the body fluid is blood, serum, or plasma. 
     
     
       14. The method of  claim 12  wherein the body fluid is blood, serum, or plasma.